MetaCap

Abeona Therapeutics (ABEO) vs InflaRx N.V. (IFRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

InflaRx N.V. (IFRX) has outperformed Abeona Therapeutics (ABEO) over the past year, losing 11.9% versus a loss of 46.0%. Over five years, IFRX leads with a -79.5% price change compared with -86.7% for ABEO. Abeona Therapeutics is the larger company by market cap ($165.3 million vs $153.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABEO-45.98%IFRX-11.86%
+141%+42%-58%
Nov 21, 20251 yearNov 20, 2026
ABEO-86.92%IFRX-78.15%
+21%-36%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABEO versus IFRX key metrics
MetricABEOIFRX
Share price$2.42$1.04
Market cap$165.31M$153.26M
1-day change-1.22%-4.59%
YTD return-54.08%+2.97%
1-year return-45.98%-11.86%
5-year return-86.74%-79.53%
EPS (TTM)$-1.16$-0.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.82M—
Net income (latest FY)$71.18M—
Gross margin73.68%—
Operating margin-1536.91%—
Net margin1223.08%—
52-week high$7.65$2.95
52-week low$2.09$0.798
Distance from 52-week high-68.37%-64.73%
Analyst consensusstrong_buynone
Avg. price target upside+542.98%+696.15%
Average volume1.66M868.66K
Shares outstanding68.31M147.37M
Employees22665
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IFRX has outperformed ABEO by 34.1 percentage points over the past year.

About Abeona Therapeutics

ABEO stock →

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees

About InflaRx N.V.

IFRX stock →

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

ABEO vs IFRX FAQ

Which is bigger, Abeona Therapeutics or InflaRx N.V.?

Abeona Therapeutics (ABEO) is larger, with a market capitalization of $165.31M compared with $153.26M for InflaRx N.V. (IFRX).

Which stock has performed better over the past year, ABEO or IFRX?

IFRX returned -11.86% over the past 12 months, compared with -45.98% for ABEO (price return, excluding dividends). Past performance does not predict future results.

Are Abeona Therapeutics and InflaRx N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons